Asset Management One Co. Ltd. Has $3.77 Million Stake in Exact Sciences Co. (NASDAQ:EXAS)

Asset Management One Co. Ltd. trimmed its position in Exact Sciences Co. (NASDAQ:EXAS) by 4.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 65,551 shares of the medical research company’s stock after selling 3,064 shares during the quarter. Asset Management One Co. Ltd.’s holdings in Exact Sciences were worth $3,772,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Huntington National Bank raised its stake in shares of Exact Sciences by 838.1% in the third quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 352 shares in the last quarter. RPg Family Wealth Advisory LLC acquired a new position in shares of Exact Sciences in the third quarter valued at $34,000. Capital Performance Advisors LLP acquired a new position in shares of Exact Sciences in the third quarter valued at $35,000. Vestor Capital LLC acquired a new position in shares of Exact Sciences in the third quarter valued at $46,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Exact Sciences in the third quarter valued at $49,000. 88.82% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on EXAS. Jefferies Financial Group upped their target price on Exact Sciences from $84.00 to $85.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. Evercore ISI dropped their price objective on Exact Sciences from $80.00 to $60.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. TD Cowen increased their price objective on Exact Sciences from $82.00 to $86.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. Stifel Nicolaus dropped their price objective on Exact Sciences from $82.00 to $67.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Finally, Barclays began coverage on Exact Sciences in a research note on Thursday, January 23rd. They set an “overweight” rating and a $70.00 price objective for the company. One analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $72.76.

Exact Sciences Price Performance

Exact Sciences stock opened at $50.48 on Thursday. The business’s 50-day simple moving average is $55.41 and its 200 day simple moving average is $60.10. The stock has a market cap of $9.34 billion, a price-to-earnings ratio of -43.14 and a beta of 1.24. Exact Sciences Co. has a 12-month low of $40.62 and a 12-month high of $79.62. The company has a quick ratio of 1.93, a current ratio of 2.12 and a debt-to-equity ratio of 0.72.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.23. Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. As a group, research analysts anticipate that Exact Sciences Co. will post -1.1 earnings per share for the current year.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.